Heptares Therapeutics, the leading GPCR drug discovery and development company, announces the publication of a new paper describing how 'reverse pharmacology', enabled by its StaR® technology, can be ...
A third set of issues to consider is the degree to which systemic small molecule CRFR1 antagonists block central CRFR1. Indeed, in the absence of a PET ligand targeting the CRFR1 receptor it is ...
Antagonists of tumor necrosis factor (TNF) have revolutionized the treatment of selected inflammatory diseases. In rheumatology, this has been most notable for ankylosing spondylitis, psoriatic ...
Addressing major unmet needs in mental health with pharmacology rooted in emerging and clinically validated neuropsychiatric biologyLead program ST-905, a potent M1/M4 muscarinic agonist, currently in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback